CanBas Co., Ltd. (JP:4575)
:4575
Want to see JP:4575 full AI Analyst Report?
4575 Stock Chart & Stats
¥787.00
-¥23.00(-2.48%)
At close: 4:00 PM EST
¥787.00
-¥23.00(-2.48%)
Day’s Range― - ―
52-Week Range¥685.00 - ¥1,558.00
Previous CloseN/A
Volume347.00K
Average Volume (3M)268.48K
Market Cap
¥13.92B
Enterprise Value¥11.79B
Total Cash (Recent Filing)¥2.83B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.06
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding19,713,655
10 Day Avg. Volume208,910
30 Day Avg. Volume268,476
Financial Highlights & Ratios
PEG Ratio1.96
Price to Book (P/B)7.69
Price to Sales (P/S)0.00
P/FCF Ratio-29.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Deleveraged Balance Sheet (zero Debt, Higher Equity)Zero reported debt and a material equity increase materially reduce refinancing and leverage risk, giving management greater strategic flexibility. Over a multimonth horizon this improves the firm's ability to fund R&D, negotiate partnerships, and survive development timelines without immediate debt pressures.
Licensing And Collaboration-oriented Revenue ModelA licensing and collaboration model scales R&D upside while sharing clinical and commercialization risk with partners. Structurally, milestone and royalty streams can become non-dilutive, provide step-change revenue upon success, and align incentives with larger commercial partners over months to years.
Signs Of Improving Cash Flow And Narrower Losses In Latest YearA reduction in cash burn and a narrower net loss indicate better capital efficiency and initial progress controlling costs. If sustained, this trend lengthens runway and reduces near-term financing needs, improving the firm's ability to advance programs and attract partner or investor support.
Bears Say
Persistent Operating And Net Losses; Revenue Near ZeroRecurring operating and net losses with effectively zero revenue reflect a pre-commercial biotech profile and imply the company cannot self-fund development. Over a multi-month horizon this increases execution risk, reliance on external capital, and uncertainty around when commercial revenues will emerge.
Sustained Negative Operating And Free Cash Flow (ongoing Cash Burn)Consistent negative operating and free cash flow necessitates continued external financing or dilutive raises, which can lengthen timelines and pressure strategy. Persisting cash burn constrains investment choices and raises the probability that future capital raises will be required within the 2–6 month horizon.
Negative Returns On Equity Indicating Value ErosionA -39% ROE signals that shareholder capital has not generated positive returns and that R&D spending has yet to translate into commercial value. Over time this undermines investor confidence and highlights the need for clear de‑risking events or successful partnerships to restore capital efficiency.
4575 FAQ
What was CanBas Co., Ltd.’s price range in the past 12 months?
CanBas Co., Ltd. lowest stock price was ¥685.00 and its highest was ¥1558.00 in the past 12 months.
What is CanBas Co., Ltd.’s market cap?
CanBas Co., Ltd.’s market cap is ¥13.92B.
When is CanBas Co., Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CanBas Co., Ltd.’s earnings last quarter?
Currently, no data Available
Is CanBas Co., Ltd. overvalued?
According to Wall Street analysts CanBas Co., Ltd.’s price is currently Overvalued.
Does CanBas Co., Ltd. pay dividends?
CanBas Co., Ltd. does not currently pay dividends.
What is CanBas Co., Ltd.’s EPS estimate?
CanBas Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CanBas Co., Ltd. have?
CanBas Co., Ltd. has 19,713,655 shares outstanding.
What happened to CanBas Co., Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CanBas Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4575
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CanBas Co., Ltd.
CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―